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Metabonomic/metabolomic studies can involve the analysis of large numbers of
samples for the detection of biomarkers and confidence in the analytical data,
generated by methods such as GC and HPLC-MS, requires active measures on the
part of the analyst. However, quality control for complex multi-component
samples such as biofluids, where many of the components of interest in the
sample are unknown prior to analysis, poses significant problems. Here the repeat
analysis of a pooled sample throughout the run, thereby enabling the analysis to
be monitored and controlled using targeted inspection of the data and pattern
recognition, is advocated as a pragmatic solution to this problem.
Introduction
The acquisition of robust and meaningful
global metabolite profiles from complex
biological samples, including biofluids,
such as plasma and urine, or tissue
extracts poses an interesting set of
problems for the analyst. Obtaining such
profiles forms the core of the rapidly
emerging sciences known variously as
metabonomics and metabolomics, where
the hope is that such techniques will
uncover important biomarkers of e.g.
toxicity or disease.1,2 Variability in the
samples can arise from a number of
sources including physiological differ-
ences (e.g. strain, gender, age, diurnal
and hormonal effects etc) (see ref. 3 for
a discussion of this topic) and variability
in the analytical method itself (both
sample preparation and analysis). For
certain techniques, such as 1H NMR
spectroscopy, where sample preparation
for biofluids is minimal, analytical repro-
ducibility has been demonstrated to be
very good.4 However, analytical methods
for metabonomics that employ either
HPLC or GC-MS generally require more
sample preparation, which in the case of
GC-based analysis is often extensive,
followed by a chromatographic separa-
tion and then mass spectrometry.
Chromatographic techniques are liable,
to a greater or lesser extent (depending
upon the technique and sample type), to
degradation of performance over time as
columns become contaminated, and the
response of mass spectrometers can also
decline with time for similar reasons. In
conventional target compound analysis
these factors are controlled by the
incorporation of internal standards, most
often a deuterated version of the analyte,
into the analytical procedure to counter,
if not entirely eliminate, such effects. In
addition, specific quality control samples
(QCs) are employed to monitor the
performance of the method. In the case
of validated methods, e.g. drug analysis,
the QCs are blank matrix samples spiked
with known concentrations of the analyte
designed to cover the range of concen-
trations that can be determined with
reasonable accuracy and precision.
These samples are usually found at the
beginning and end of the sample set and
also scattered randomly through the
analytical run. Examination of the QC
data at the end of the analysis against a
set of predefined criteria enables the
analytical scientist to decide whether or
not to accept or reject the batch. In such
targeted analysis, retention is also mon-
itored but, given the specificity of the
technique, some variation through the
run is more easily tolerated. Such rigor is
not merely good analytical practice but,
where data is to be used to support drug
registration, is covered by regulatory
guidance.5
This approach is not viable for meta-
bonomics analysis for the following
reasons.
(1) The samples typically contain 100s
to 1000s of components covering a wide
range of concentrations and structural
types, of variable and unknown MS
response.
(2) The bulk of the analytes in the
sample are unknown prior to the analysis
and indeed, because of limitations in the
state of our knowledge at the moment,
potential biomarkers may remain uni-
dentified at the end.
(3) By definition, stable isotope
labelled internal standards cannot be
used where the identity of the analytes
are unknown, even if it were a realistic
economic proposition to prepare them all
and spike them in.
(4) The post analysis processing of the
data, if it makes use of the 3-dimensional
data set provided by mass, retention
and intensity information, cannot easily
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tolerate significant changes in chromato-
graphic retention or mass spectrometer
response.
A partial solution to this problem is to
accept that it is not possible to control
the analysis of all of the compounds and
instead to opt for the control of a limited
number of them for which deuterated
internal standards are available. This is
done in the hope that if these analytes
‘‘behave’’ themselves then the system is
under control and thus the analysis of all
of the remaining analytes is also under
control. The selected standards can be
spiked in to samples prior to analysis as
pseudo internal standards, or run simply
as QCs alongside the test samples. Whilst
such an approach might have been
sustainable a few years ago, increasing
experience of quantitative HPLC-MS,
where ion suppression/ion enhancement
and source contamination can cause
highly variable responses during analysis,
has done much to dim such optimism
amongst the authors. In addition to MS-
related effects, changes in column selec-
tivity are also likely as columns age,
which might well lead to differential
changes in retention for e.g. bases vs.
acids etc., especially if in HPLC silano-
philic interactions are involved in the
retention mechanisms of any of the
analytes.
Against this backdrop we have
attempted to formulate a pragmatic
strategy for controlling the multi-compo-
nent, multi-parametric, analytical pro-
cess encountered in metabonomics. At
the heart of this approach are the
samples themselves that, between them,
contain all of the analytes that will be
encountered during the analysis.
We therefore advocate taking aliquots
from every sample which are then com-
bined in a representative pool sample.
The pool sample is then split to form a
multi-sample QC set which is analysed at
the beginning, end and randomly
through the analytical run. The same
pool sample can also be used for
performing a system suitability test prior
to beginning the main analytical run if
required. For batches of 100 or so
samples the QCs would represent a
minimum of 10% of the total analysed
(more if the batch was small).
Post analysis, the pool sample QC data
can be examined visually for gross
changes to give a rapid assessment of
how well the run has gone. Similarly, a
small number of selected components
can be rapidly screened for peak shape,
intensity, mass accuracy and retention
time against predetermined acceptance
criteria. Assuming that these criteria are
met then the whole data set can be taken
forward for initial multivariate statistical
analysis, using an unsupervised method
such as principal components analysis
(PCA) with the QC data expected to
cluster closely together, and show no
time related trends (supervised methods
should not be used as these will ‘‘force’’
the QCs to cluster together potentially
masking variability). If statistical analy-
sis reveals more subtle, time-related,
changes the analyst can use the results
to determine if there was a gradual
change during the analysis or whether a
sudden deterioration had occurred at
some point midway through the analysis.
Here we give two examples of the use
of this strategy for the control of GC-MS
analysis of rat plasma samples and the
reversed-phase gradient HPLC-ToF-MS
of human urine.
For GC-MS analysis, plasma samples
from 4 different strains of rat (100 mL)
were protein precipitated using 3 volumes
of acetonitrile, followed by centrifuga-
tion, and then 100 mL of each super-
natant was evaporated to dryness prior
to derivatisation. In addition, prior to
analysis, 50 mL of each original sample
were pooled to generate the QC and
aliquots of 100 mL of this pooled sample
were taken through the same process. All
samples were then subjected to a double
derivatisation procedure involving meth-
oxylamine hydrochloride and then
MSTFA at 37 uC.6 Capillary GC-MS,
using a 20 m 6 180 mm 6 0.18 mm DB5
column, with a temperature gradient
from 85 to 320 uC, was then used to
generate profiles in both EI and CI
modes (separate batches of sample were
used for the EI and CI runs). The result-
ing GC-MS data were processed using
the Waters MarkerLynx Application
Manager. The results of the PCA of the
GC-EIMS and GC-CIMS data are
shown in Fig. 1 and 2 respectively. As
these figures show, despite extensive and
lengthy sample preparation and subse-
quent GC-MS, the QC samples generally
cluster closely together in the PCA scores
plot, providing a degree of confidence
that the results obtained for the test
samples are suitable for further data
analysis with the aim of finding biomar-
kers. The one QC sample which does not
cluster with the others in the GC-CIMS
example (Fig. 2) was the second injection
of the batch (the first having been
automatically discarded). Such beha-
viour in the first few samples run in both
GC and LC-MS is not unusual in our
experience and, as discussed below, has
led us to a change our analytical practice.
For UPLC-MS analysis, urine samples
from a set of human samples (100 mL)
were diluted by the ratio 1 : 4 with 0.1%
formic acid, followed by centrifugation,
and then injected onto the LC-MS. In
addition, prior to analysis, 50 mL of each
original sample were pooled to generate a
QC sample and aliquots of 100 mL of this
pooled sample were taken through the
same process. The samples were analysed
on a Waters ACQUITY UPLC system
Fig. 1 All samples were plasma from 20 week
old male rats. The figure shows the PCA scores
plot of PC1 versus PC2 obtained from the
GC-EIMS data. Key: (&) QCs; (#) Wistar-
derived rats; (e) Zucker (fa/fa) rats; (n) Zucker
lean/(fa) cross; (,) Zucker lean rats.
Fig. 2 All samples were plasma from 20 week
old male rats. The figure shows the PCA scores
plot of PC1 versus PC2 obtained from the
GC-CIMS data. Key: (&) QCs; (#) Wistar-
derived rats; (e) Zucker (fa/fa) rats; (n) Zucker
lean/(fa) cross; (,) = Zucker lean rats.
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with a 10 cm 6 2.1 mm, 1.7 mm BEH
C18 ACQUITY column coupled to a
QTof Micro mass spectrometer. The
column was maintained at approximately
40 uC and elution was performed using a
gradient of 0.1% formic acid and acet-
onitrile. The resulting LC-MS data were
processed using the Waters MarkerLynx
Application Manager, with statistical
analysis in SIMPCA-P. The results for
the PCA of the UPLC-MS data are
shown in Fig. 3, and once again show
that, although there is some variability in
the QCs, these samples nevertheless
cluster closely together and indicate that
the analysis is under control.
In any QC approach the question of
course then arises as to how ‘‘tight’’ the
data should be to be considered accep-
table. Currently our practice is to use the
QC data as a means of rejecting batches
as, if the QCs are widely scattered in the
scores plot, it is fairly easy to decide that
the analysis was not fit for purpose.
However, we are not then advocating the
blind acceptance of the remaining
batches but, having filtered out obviously
bad data, it then seems reasonable invest
more time analysing the results from runs
that appear, on the basis of the PCA
result, to have been under good analy-
tical control. For potential biomarkers
detected in the samples it would then be
reasonable to examine the reproducibility
of the method for that component,
taking into account the intensity of the
ion of interest (so that intense ions giving
good signal-to-noise (S/N) ratios should
perhaps be required to exhibit a higher
degree of precision than those of low
intensity). In this respect the FDAs
guidance on bioanalytical method vali-
dation5 would probably provide a good
starting point. Thus, coefficients of var-
iation of less than 15% would be required
for ions with good S/N and 20% for those
with an S/N of perhaps only 3 times
greater than background.
For both HPLC and GC, when the
potential biomarkers have been identified
by statistical analysis of the data, it is
possible to re-examine the QC data
specifically to look at the variability of
the results obtained for those specific
ions in the QC-data set. Once satisfied
that the results are unlikely to be
artefacts of the analysis, it may then be
worth devoting the time to the identifica-
tion of these interesting metabolites with
the aim of developing specific and
validated methods for them to prove
the hypothesis that they are indeed
biomarkers for the biological state under
investigation.
On the basis of our observations made
using this approach we know that the first
few analytical runs are the most variable
(e.g. see the GC-CIMS data above).
Whilst the reasons for this are not clear
the consequences are obvious, and we
would therefore strongly advocate that,
prior to beginning an analytical run,
several QC samples are run first to
effectively ‘‘condition’’ the chromato-
graphic system. The data from these initial
runs should not form part of total QC
data set used subsequently to ‘‘validate’’
the quality of the metabolite profiles
generated, but could be used as supporting
data to show system suitability.
The methodology outlined here has
been specifically designed for use on
relatively small batches of samples (from
a few tens of samples up to a few
hundred) that could be accommodated
in a single analytical run on one instru-
ment. Such a sample size would be
typical of the sorts of numbers generated
in toxicological studies in animal species,
investigative studies in disease models or
Fig. 3 The PCA scores plot obtained following the UPLC-MS analysis of human urine samples (grey circles). To generate QCs 50 mL of each
original sample were pooled (black squares). The samples were analysed by reversed-phase UPLC on a 10 cm 6 2.1 mm, 1.7 mm BEH C18
ACQUITY column coupled to a QTof Micro mass spectrometer.
This journal is  The Royal Society of Chemistry 2006 Analyst, 2006, 131, 1075–1078 | 1077
small scale studies in humans. In such
applications, the QC policy described
here seems to be appropriate to demon-
strate ‘‘within day’’ analytical control.
Whether or not the use of such QCs
would enable ‘‘split’’ batches, run on
different days, to be combined is less
clear. This is clearly an area that requires
further investigation as there are circum-
stances when it would be highly desirable
to be able to combine ‘‘between’’ day
datasets (e.g., after instrument failure
partway through a run, or where there
are more samples than can be easily
accommodated in a single analytical
run).
There are, in addition, the QC require-
ments of larger epidemiological or clinical
studies, to be considered. Such types of
study are more problematic because the
large numbers of samples collected (often
over a period of some years) means that
analysis in a single batch is not possible.
In such cases, as there is a need to also
ensure between batch as well as within
batch data quality, it would almost
certainly not be practicable to use a pool
QC prepared from the samples them-
selves, and instead the use of a single bulk
sample prepared at the start of the study
and split into a large number of sub-
aliquots and stored with the study sam-
ples may be preferable. However, such an
approach assumes sample stability over
the collection period of the study.
Clearly, if confidence is to be placed in
the data generated from complex sample
analysis of the type encountered in
metabonomics studies, some assurance
of the quality of the data is required. This
is especially the case if data are to be
submitted in support of regulatory stu-
dies, but also forms an important part of
any analytical study in this area. There
are already initiatives working towards
the standardisation of the reporting of
metabonomics data,7 and quality control
procedures need to form part of this
debate. Probably the best way to use the
approach described above is as an initial
screen of the analytical results. Thus, if
the QC data is highly variable the run
fails and re-analysis is required. In
contrast, if the QC data are close, this
does not necessarily mean that the
analysis is satisfactory, but allows provi-
sional acceptance of the run, and justifies
devoting more time to a more exhaustive
interrogation of the data with more
advanced statistical procedures.
Whilst this approach of repeat analysis
of a pooled sample can be criticized in
any number of ways it at least has the
advantages of ease of implementation,
speed (it can be performed by the analyst
at the instrument) and relevance to the
samples being analysed. We therefore
offer it as one possible route towards a
viable QC policy for monitoring global
metabolite profiling that covers that part
of the analytical process involving sam-
ple preparation and chromatographic/
mass spectroscopic analysis, in the hope
of stimulating a debate on what we
believe to be an important problem
facing investigators in this area.
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